TN
TNGX
Tango Therapeutics, Inc.
$29.56
-6.35%
$4.6B
No data for this timeframe.
Vol
Market Cap$4.6B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders7 funds
Inst. Value$111.9M
Inst. Activity6 buys / 1 sells
Insider Activity0B / 10S
Insider Net $-$4.2M
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases2
Recent Activity
Jun 10, 2026
Press
Tango Therapeutics priced a $600M underwritten offering of 18.2M common shares and pre-funded warrants at $30/share, wit
Impact 6/10
Jun 10, 2026
offering
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
<p>BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a
Jun 8, 2026
SEC
Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $
424B5 — Impact 7/10
Jun 8, 2026
SEC
Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Me
8-K — Impact 7/10
Jun 5, 2026
Insider
Calhoun Lesley Ann sold 4,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Calhoun Lesley Ann sold 25,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Rothenberg Mace sold 25,000 shares
Director @ $0.00 ($0.00)
May 8, 2026
SEC
Tango Therapeutics formalized the separation of former CFO Daniella Beckman, who was terminated without cause effective
8-K — Impact 2/10
Price Targets
$36.91
+24.9% upside
Strong Buy
Current $29.56
Low $24.00
Median $35.00
High $69.00
11 analysts
$24.00
$69.00
Analyst Ratings
6Strong Buy
8Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jun 9, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Jun 8, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| May 15, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 15, 2026 | Piper Sandler | DOWNGRADE | Overweight → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.33 ▲ +0.8% | $-0.35 — $-0.29 | 7% YoY | 11 |
| Next Q | $-0.34 ▼ -0.5% | $-0.38 — $-0.26 | -360% YoY | 11 |
| Current FY | $-1.33 ▲ +1.2% | $-1.44 — $-1.15 | -53% YoY | 11 |
| Next FY | $-1.58 ▲ +3.2% | $-1.87 — $-1.24 | -19% YoY | 10 |
Latest Reports
BEARISH
Press
6/10
Tango Therapeutics priced a $600M underwritten offering of 18.2M common shares and pre-funded warrants at $30/share, wit
Jun 10, 2026
BEARISH
424B5
7/10
Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $
Jun 8, 2026
BULLISH
8-K
7/10
Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Me
Jun 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $59.8M | ADD |
| FMR LLC | $25.4M | DOUBLED |
| MORGAN STANLEY | $12.6M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.5M | ADD |
| BANK OF AMERICA CORP | $4.2M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Calhoun Lesley | A | $0.00 |
| Jun 5, 2026 | Calhoun Lesley | A | $0.00 |
| Jun 5, 2026 | Rothenberg Mace | A | $0.00 |
| Jun 5, 2026 | Rothenberg Mace | A | $0.00 |
| Jun 5, 2026 | Lee Sung | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $111.9M total value (12,624,991 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 6 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 6,750,977 | $59.8M | 53.5% | ADD +33.6% |
| 2 | FMR LLC | 2,867,548 | $25.4M | 22.7% | DOUBLED +44524.2% |
| 3 | MORGAN STANLEY | 1,421,794 | $12.6M | 11.3% | DOUBLED +464.7% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 840,992 | $7.5M | 6.7% | ADD +27.8% |
| 5 | BANK OF AMERICA CORP /DE/ | 478,062 | $4.2M | 3.8% | DOUBLED +207.5% |
| 6 | TWO SIGMA INVESTMENTS, LP | 144,432 | $1.3M | 1.1% | DOUBLED +550.1% |
| 7 | WELLS FARGO & COMPANY/MN | 121,186 | $1.1M | 1.0% | DOUBLED +120.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 5,052,003 | 6,750,977 | +33.6% | $59.8M | 2025-Q4 |
| FMR LLC | DOUBLED | 6,426 | 2,867,548 | +44524.2% | $25.4M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 251,793 | 1,421,794 | +464.7% | $12.6M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 658,292 | 840,992 | +27.8% | $7.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 155,447 | 478,062 | +207.5% | $4.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 55,005 | 121,186 | +120.3% | $1.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 55,300 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 4,026,800 | 5,052,003 | +25.5% | $42.4M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 534,621 | 251,793 | -52.9% | $2.1M | 2025-Q3 |
| UBS Group AG | TRIM | 277,102 | 160,478 | -42.1% | $1.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 47,145 | 155,447 | +229.7% | $1.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 22,218 | 144,432 | +550.1% | $1.2M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 250,519 | 534,621 | +113.4% | $2.7M | 2025-Q2 |
| UBS Group AG | ADD | 153,335 | 277,102 | +80.7% | $1.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 174,500 | 65,500 | -62.5% | $335.4K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 22,795 | 49,217 | +115.9% | $252.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 351,489 | 47,145 | -86.6% | $241.4K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 52,902 | 22,218 | -58.0% | $113.8K | 2025-Q2 |
| FMR LLC | TRIM | 10,742 | 5,578 | -48.1% | $28.6K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 21,500 | 174,500 | +711.6% | $239.1K | 2025-Q1 |
| UBS Group AG | TRIM | 414,473 | 153,335 | -63.0% | $210.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 1,632,559 | 107,602 | -93.4% | $147.4K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 2,698,725 | 1,632,559 | -39.5% | $5.0M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 14,693 | 22,292 | +51.7% | $68.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 21,500 | — | $66.4K | 2024-Q4 |
8 unique insiders with 10 transactions. Net insider value: -$4.2M ($0.00 bought, $4.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Calhoun Lesley Ann | Director | A | 4,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Calhoun Lesley Ann | Director | A | 25,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Rothenberg Mace | Director | A | 25,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Rothenberg Mace | Director | A | 4,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Lee Sung | Director | A | 3,570 | $0.00 | $0.00 |
| Jun 5, 2026 | Lee Sung | Director | A | 570 | $0.00 | $0.00 |
| Jun 5, 2026 | Ketchum John B | Director | A | 4,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Ketchum John B | Director | A | 25,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Crystal Adam | President, R&D | M | 27,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Crystal Adam | President, R&D | M | 27,000 | $5.20 | $140.4K |
| Jun 1, 2026 | Crystal Adam | President, R&D | SELL | 6,140 | $22.25 | $136.6K |
| May 1, 2026 | Gall Matthew | Chief Financial Officer | A | 40,000 | $0.00 | $0.00 |
| May 1, 2026 | Gall Matthew | Chief Financial Officer | A | 240,000 | $0.00 | $0.00 |
| May 1, 2026 | Crystal Adam | President, R&D | M | 27,000 | $5.20 | $140.4K |
| May 1, 2026 | Crystal Adam | President, R&D | SELL | 25,900 | $21.19 | $548.9K |
| May 1, 2026 | Crystal Adam | President, R&D | M | 27,000 | $0.00 | $0.00 |
| Apr 29, 2026 | Lee Sung | Director | A | 12,300 | $0.00 | $0.00 |
| Apr 29, 2026 | Lee Sung | Director | A | 5,200 | $0.00 | $0.00 |
| Apr 15, 2026 | Crystal Adam | President, R&D | M | 38,460 | $5.20 | $200.0K |
| Apr 15, 2026 | Crystal Adam | President, R&D | SELL | 38,460 | $25.00 | $961.5K |
| Apr 15, 2026 | Crystal Adam | President, R&D | M | 38,460 | $0.00 | $0.00 |
| Apr 1, 2026 | Crystal Adam | President, R&D | M | 27,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Crystal Adam | President, R&D | SELL | 27,000 | $21.20 | $572.5K |
| Apr 1, 2026 | Crystal Adam | President, R&D | M | 27,000 | $5.20 | $140.4K |
| Mar 25, 2026 | Crystal Adam | President, R&D | M | 12,000 | $5.20 | $62.4K |
| Mar 25, 2026 | Crystal Adam | President, R&D | SELL | 12,000 | $20.11 | $241.3K |
| Mar 25, 2026 | Crystal Adam | President, R&D | M | 12,000 | $0.00 | $0.00 |
| Mar 5, 2026 | Crystal Adam | President, R&D | SELL | 20,251 | $15.00 | $303.8K |
| Feb 25, 2026 | Crystal Adam | President, R&D | SELL | 54,345 | $12.77 | $694.2K |
| Feb 3, 2026 | Weber Barbara | Director, Executive Chair | SELL | 30,186 | $12.26 | $370.0K |
| Feb 3, 2026 | Crystal Adam | President, R&D | SELL | 18,251 | $12.26 | $223.7K |
| Feb 3, 2026 | Beckman Daniella | Chief Financial Officer | SELL | 10,204 | $12.26 | $125.1K |
| Feb 2, 2026 | Weber Barbara | Director, Executive Chair | A | 37,522 | $0.00 | $0.00 |
| Feb 2, 2026 | Weber Barbara | Director, Executive Chair | A | 222,132 | $0.00 | $0.00 |
| Feb 2, 2026 | Crystal Adam | President, R&D | A | 47,460 | $0.00 | $0.00 |
| Feb 2, 2026 | Crystal Adam | President, R&D | A | 284,760 | $0.00 | $0.00 |
| Feb 2, 2026 | Beckman Daniella | Chief Financial Officer | A | 44,330 | $0.00 | $0.00 |
| Feb 2, 2026 | Beckman Daniella | Chief Financial Officer | A | 265,980 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 4.3/10.
BEARISH
424B5
7/10
Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering,
Jun 8, 2026
BULLISH
8-K
7/10
Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combinatio
Jun 8, 2026
NEUTRAL
8-K
2/10
Tango Therapeutics formalized the separation of former CFO Daniella Beckman, who was terminated with
May 8, 2026
NEUTRAL
3
2/10
Matthew Gall, CFO of Tango Therapeutics, filed a Form 3 and granted a power of attorney to Julie Fog
Apr 24, 2026
NEUTRAL
DEFA14A
3/10
Tango Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Cla
Apr 17, 2026
NEUTRAL
8-K
3/10
Tango Therapeutics announced the appointment of Matthew Gall as Chief Financial Officer, effective A
Apr 15, 2026
MIXED
8-K
6/10
Tango Therapeutics reported financial results for Q4 and full year 2025, showing a decline in revenu
Mar 5, 2026
Current analyst consensus: Buy (78% buy). Based on 18 analysts: 6 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$36.91 mean target
+24.9% upside
Strong Buy (1.33)
$24.00 Low
$69.00 High
| Metric | Value |
|---|---|
| Current Price | $29.56 |
| Target Low | $24.00 |
| Target Mean | $36.91 |
| Target Median | $35.00 |
| Target High | $69.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.33 | $-0.35 | $-0.29 | 6.8% | +0.8% | 5↑ 3↓ | $0.0B | -100.0% | 11 |
| Next Q 2026-09-30 |
$-0.34 | $-0.38 | $-0.26 | -360.1% | -0.5% | 5↑ 3↓ | $0.0B | -100.0% | 11 |
| Current FY 2026-12-31 |
$-1.33 | $-1.44 | $-1.15 | -52.7% | +1.2% | 5↑ 4↓ | $0.0B | -100.0% | 11 |
| Next FY 2027-12-31 |
$-1.58 | $-1.87 | $-1.24 | -18.9% | +3.2% | 3↑ 2↓ | $0.0B | 0.0% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.326 | |
| 7d ago | $-0.325 | -0.002 |
| 30d ago | $-0.329 | +0.003 |
| 60d ago | $-0.327 | +0.001 |
| 90d ago | $-0.323 | -0.003 |
9 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jun 9, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jun 8, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| May 15, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 15, 2026 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
| May 14, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| May 14, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 27, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 2, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 11, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | Mizuho | INITIATE | — | Outperform |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 8 | 4 | 0 | 0 | 78% | |
| May 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Jan 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
2 stocks for 12 months?
▲ 1
💬 1
⚡ 0.5
Jun 10, 2026
offering
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
<p>BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to
Jun 8, 2026
offering
Tango Therapeutics Announces Proposed $500 Million Public Offering
<p>BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to
Jun 8, 2026
other
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
<p align="center"><em>Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib
Jun 5, 2026
other
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation
Jun 2, 2026
short_volume
Short Volume: TNGX — 71.2% short (0.7M / 1.0M)
Short: 679,508 | Exempt: 2,047 | TRF Vol: 954,886 | Short Ratio: 71.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: TNGX — 65.5% short (0.7M / 1.1M)
Short: 741,885 | Exempt: 100 | TRF Vol: 1,133,097 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: TNGX — 63.4% short (1.0M / 1.6M)
Short: 992,956 | Exempt: 9,420 | TRF Vol: 1,567,332 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: TNGX — 61.2% short (1.8M / 3.0M)
Short: 1,817,791 | Exempt: 43,365 | TRF Vol: 2,968,347 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: TNGX — 74.7% short (2.3M / 3.0M)
Short: 2,261,233 | Exempt: 22,640 | TRF Vol: 3,028,146 | Short Ratio: 74.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
<p align="center"><em>First clinical data from PRMT5/RAS(ON) combination trial to be pre</em><em>sented in 2026</em></p>
May 13, 2026
earnings_calendar
TNGX Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
short_volume
Short Volume: TNGX — 58.1% short (0.4M / 0.6M)
Short: 360,676 | Exempt: 9,500 | TRF Vol: 620,416 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
TNGX Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
short_interest
FTD: TNGX — 121,894 shares ($2.9M) failed to deliver
Settlement: 20260507, Price: $23.62, FTD Value: $2,879,136.28, TANGO THERAPEUTICS INC COM (DE
May 5, 2026
short_volume
Short Volume: TNGX — 57.1% short (0.6M / 1.0M)
Short: 592,666 | Exempt: 2,034 | TRF Vol: 1,037,822 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
Clinical Trial
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Phase Phase 2 — TERMINATED